TY - JOUR
T1 - Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases
AU - Iriki, Hisato
AU - Takahashi, Hayato
AU - Amagai, Masayuki
N1 - Funding Information:
This work was supported by Grants-in-Aid for Scientific Research (S) Grant Number JP21229014, JP17109012 (to MA), and (A) Grant Number JP19H01051 (to HT) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Health and Labor Sciences Research Grants for Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare of Japan (20FC1052) (to MA and HT).
Publisher Copyright:
© 2022 The Authors
PY - 2023/4
Y1 - 2023/4
N2 - OX40 is an important costimulatory molecule for T-cell expansion and survival. Because OX40 is expressed on most T-cell subsets, it is an attractive therapeutic target for a variety of T-cell‒mediated diseases. Clinical trials are already underway for some skin inflammatory diseases. In this review, we present various observations that improve our understanding of how OX40-targeted therapy can be applied for skin inflammatory diseases, such as atopic dermatitis and psoriasis, T helper (Th)2- and Th17-mediated diseases, respectively. The important OX40/OX40L-mediated interaction between T cells and other immune cells is also discussed in terms of skin autoimmune diseases, such as alopecia areata and pemphigus. Regulatory T cells (Tregs) highly express OX40, and the skin harbors a large Treg population; thus, understanding how OX40-targeted treatment acts on Tregs is vital for the development of therapeutic strategies for various skin diseases.
AB - OX40 is an important costimulatory molecule for T-cell expansion and survival. Because OX40 is expressed on most T-cell subsets, it is an attractive therapeutic target for a variety of T-cell‒mediated diseases. Clinical trials are already underway for some skin inflammatory diseases. In this review, we present various observations that improve our understanding of how OX40-targeted therapy can be applied for skin inflammatory diseases, such as atopic dermatitis and psoriasis, T helper (Th)2- and Th17-mediated diseases, respectively. The important OX40/OX40L-mediated interaction between T cells and other immune cells is also discussed in terms of skin autoimmune diseases, such as alopecia areata and pemphigus. Regulatory T cells (Tregs) highly express OX40, and the skin harbors a large Treg population; thus, understanding how OX40-targeted treatment acts on Tregs is vital for the development of therapeutic strategies for various skin diseases.
UR - http://www.scopus.com/inward/record.url?scp=85149878193&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149878193&partnerID=8YFLogxK
U2 - 10.1016/j.jid.2022.11.009
DO - 10.1016/j.jid.2022.11.009
M3 - Review article
C2 - 36842860
AN - SCOPUS:85149878193
SN - 0022-202X
VL - 143
SP - 545
EP - 553
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
IS - 4
ER -